09:00 AM EDT, 05/08/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our 12-month target price by $3 to $78, 15.4x our 2024 EPS estimate (down $0.03 to $5.07; we lower our 2025 estimate by $0.06 to $5.61), a discount to HSIC's three- and five-year historical averages of 16.2x and 18.1x, respectively. Q1 EPS of $1.10 vs. $1.21 beat consensus by $0.09. Sales of $3.17B rose 3.7% Y/Y, though HSIC estimates a 3%-4% headwind during the quarter due to lingering impact from the October 2023 cybersecurity incident. Global Dental sales (60% of total) rose 0.8%, and Global Medical sales (33% of total) rose 7.3% Y/Y. Global Technology sales (7% of total) rose 13.8% Y/Y. Adjusted operating margin fell to 7.11% from 7.68% in the prior-year quarter, and our full-year margin expectations are closer to 6.0% vs. 6.5%-7.0% previously. HSIC lowered its 2024 sales growth midpoint to 9% from 10% but maintained its earnings guidance.